http://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0168407
http://science.sciencemag.org/content/351/6273/617
New drug might help cats with HCM: "The novel drug, MYK-461, proved effective in a study of five cats with a naturally occurring form of inherited hypertrophic cardiomyopathy (HCM)...eliminated left ventricular obstruction in five cats with HCM...MYK-461 was already shown to stop the thickening of the ventricle walls in mice."
Here's the paper about the new trial drug discovered for the treatment of HCM. Understand the drug treats obstruction, not something all HCM cats have; and it may not decrease the progression of the disease, just some physical issues of the disease. But only time will tell. Keep an eye on this drug. Let me know if you read more about future developments. I'll try to stay aware of it. "Treatment with MYK-461 reduced contractility, eliminated systolic anterior motion of the mitral valve and relieved LVOT pressure gradients in an exposure-dependent manner. Our findings provide proof of principle that acute reduction in contractility with MYK-461 is sufficient to relieve LVOT obstruction. Further, these studies suggest that feline HCM will be a valuable translational model for the study of disease pathology, particularly LVOT obstruction."
http://science.sciencemag.org/content/351/6273/617
New drug might help cats with HCM: "The novel drug, MYK-461, proved effective in a study of five cats with a naturally occurring form of inherited hypertrophic cardiomyopathy (HCM)...eliminated left ventricular obstruction in five cats with HCM...MYK-461 was already shown to stop the thickening of the ventricle walls in mice."
Here's the paper about the new trial drug discovered for the treatment of HCM. Understand the drug treats obstruction, not something all HCM cats have; and it may not decrease the progression of the disease, just some physical issues of the disease. But only time will tell. Keep an eye on this drug. Let me know if you read more about future developments. I'll try to stay aware of it. "Treatment with MYK-461 reduced contractility, eliminated systolic anterior motion of the mitral valve and relieved LVOT pressure gradients in an exposure-dependent manner. Our findings provide proof of principle that acute reduction in contractility with MYK-461 is sufficient to relieve LVOT obstruction. Further, these studies suggest that feline HCM will be a valuable translational model for the study of disease pathology, particularly LVOT obstruction."
No comments:
Post a Comment